Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Sunil Manjila

Neurological Surgery Ann Arbor, MI Medical Doctor

NPI 1912160409 CMS profile 1382216

2641 Aspen Rd, Ste 101, Ann Arbor, MI 48108

Open in the dashboard

General payments

$6,307

61 records reported · program years 2019–2024

Research payments

$5,208

Paid to them · 7 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,349 paid to institutions, not to them · program year 2022

Through program year 2024, Sunil Manjila of Ann Arbor, MI is reported in the CMS Open Payments database as having received $6,307 across 61 general payments and $5,208 in research payments paid to them. Separately, studies naming them as principal investigator received $5,349 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $132 2
2023 General $1,607 16
2022 General $3,820 30
2021 General $48 1
2020 General $441 6
2020 Research $1,783 2
2019 General $258 6
2019 Research $3,425 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sunil Manjila
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Sunil Manjila were reported at $0. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Sunil Manjila Neurological Surgery median Middle half National median
2019 $258 $582 $138–$3,006 $163
2020 $441 $294 $76–$2,174 $114
2021 $48 $387 $105–$2,432 $132
2022 $3,820 $542 $139–$2,989 $149
2023 $1,607 $534 $145–$2,697 $160
2024 $132 $574 $155–$3,046 $164
2025 $0 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medtronic, Inc. $2,852 33 payments
  2. Aesculap, Inc. $2,665 13 payments
  3. Boston Scientific Corporation $216 3 payments
  4. Medtronic USA, Inc. $201 3 payments
  5. Stryker Corporation $158 2 payments
  6. Providence Medical Technology, Inc. $76 1 payment
  7. Abbott Laboratories $76 2 payments
  8. Olympus America Inc. $31 1 payment
  9. AbbVie, Inc. $15 1 payment
  10. Pfizer Inc. $12 1 payment
  11. Other $5 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Travel and Lodging $4,730 22 payments
  2. Food and Beverage $1,577 39 payments
Products named General payments · program years 2019–2024
  1. PROGAV 2.0 $2,665 13 payments
  2. STEALTHSTATION S8 PLATFORM $1,499 14 payments
  3. CD HORIZON SPINAL SYSTEM $1,118 15 payments
  4. GENERAL - PAIN MANAGEMENT $216 3 payments
  5. NSE - SONOPET $142 1 payment
  6. SYNCHROMED $99 1 payment
  7. ACTIVOS 10 BONE CEMENT $93 1 payment
  8. KYPHON EXPRESS II KYPHOPAK TRAY $78 1 payment
  9. CAVUX Cervical Cage $76 1 payment
  10. DTRAX Spinal System $76 1 payment
  11. Other $490 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Arbor Pharmaceuticals, Inc. $5,208 7 payments

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

4,486

Median for Neurosurgery: 83

Drug cost

$216,921

Median for Neurosurgery: $872

Branded share of claims

21%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 48 $44,130
Oxymorphone Hcl Er Oxymorphone Hcl Brand 22 $34,976
Naloxone Hcl Generic 457 $33,379
Farxiga Dapagliflozin Propanediol Brand 21 $19,009
Jardiance Empagliflozin Brand 14 $11,761
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $11,395
Oxycodone Hcl Generic 494 $10,066
Naproxen Generic 522 $6,900
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 270 $5,799
Albuterol Sulfate Hfa Albuterol Sulfate Brand 180 $5,589

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record